CYT006-AngQb
CYT006-AngQb
CYT006-AngQb (pronounced as: S-Y-T-Zero-Zero-Six-Ang-Q-b) is a vaccine candidate that was developed for the treatment of hypertension (high blood pressure). It was developed by Cytos Biotechnology, a Swiss biotechnology company.
Etymology
The name "CYT006-AngQb" is derived from the company's name, Cytos, and the specific code assigned to the vaccine candidate. The "AngQb" part of the name refers to the Angiotensin II protein, which is targeted by the vaccine.
Mechanism of Action
CYT006-AngQb works by stimulating the body's immune system to produce antibodies against the Angiotensin II protein. This protein is a potent vasoconstrictor, which means it narrows blood vessels and increases blood pressure. By blocking the action of Angiotensin II, the vaccine helps to lower blood pressure.
Clinical Trials
Several clinical trials have been conducted to test the safety and efficacy of CYT006-AngQb. The results have shown that the vaccine is well-tolerated and can lead to significant reductions in blood pressure.
Related Terms
External links
- Medical encyclopedia article on CYT006-AngQb
- Wikipedia's article - CYT006-AngQb
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski